KIAA1524 Antibody

說明書

中文名稱：

KIAA1524兔多克隆抗體
貨號：

CSB-PA980052
規格：

￥1100
圖片：
Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A431 cells, lovo cells, Primary antibody: CSB-PA980052(KIAA1524 Antibody) at dilution 1/597, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

Q8TCG1
基因名：

CIP2A
別名：

Cancerous inhibitor of PP2A antibody; Cancerous Inhibitor of Protein Phosphatase 2A antibody; CIP2A antibody; CIP2A_HUMAN antibody; FLJ12850 antibody; Kiaa1524 antibody; MGC163436 antibody; p90 antibody; p90 autoantigen antibody; Protein CIP2A antibody
宿主：

Rabbit
反應種屬：

Human,Mouse
免疫原：

Fusion protein of Human KIAA1524
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,WB

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
WB	1:500-1:2000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Oncoprotein that inhibits PP2A and stabilizes MYC in human malignancies. Promotes anchorage-independent cell growth and tumor formation.
基因功能參考文獻：
1. Study revealed that the mechanism underlying the involvement of CIP2A in cisplatin sensitivity enhancement is that CIP2A mediates cisplatininduced cell apoptosis and DNA damage. PMID: 30106121
2. Aberrant expression of cancerous inhibitor of protein phosphatase 2A (CIP2A) indicates poor prognosis and promotes EMT and metastasis. PMID: 30119963
3. CIP2A overexpression is associated with lung metastasis in colorectal cancer . PMID: 30144452
4. MycN/CIP2A-mediated cell-fate bias may reflect a possible mechanism underlying early priming of some aggressive forms of neuroblastoma. PMID: 30021854
5. that CIP2A plays an important role in the carcinogenesis of endometrioid adenocarcinoma PMID: 29274810
6. CIP2A has higher expression in DDP-resistant GC patients. DDP-resistant GC patients with high CIP2A expression presented with poorer overall survival rates than those with low CIP2A expression. PMID: 29103022
7. High CIP2A expression is associated with laryngeal carcinoma. PMID: 28656258
8. High expression of CIP2A is associated with cisplatin resistant gastric cancer. PMID: 28534965
9. These data reveal that CIP2A is a crucial mediator of FN-induced bladder cancer cell proliferation via enhancing the stabilization of beta-catenin. PMID: 28521777
10. confirmed the high mRNA and protein expression levels of CIP2A in hepatocellular carcinoma (HCC), and found high CIP2A mRNA expression level was associated with unfavorable overall and recurrence-free survival in patients with HCC PMID: 29175329
11. High CIP2A expression is associated with gemcitabine resistance in pancreatic cancer. PMID: 26894380
12. These results are the first evidence that the inhibition of HDAC1 by (S)-2 downregulates CIP2A transcription PMID: 27029072
13. Membranous CIP2A expression as a potential novel prognostic and predictive indicator for tamoxifen resistance. PMID: 29034804
14. Cip2a effectively promotes triple-negative breast cancer (TNBC) cell cycle progression and tumor growth via regulation of PP2A/c-myc/p27Kip1 signaling, which could serve as a potential therapeutic target for TNBC patients. PMID: 27694903
15. poor prognosis of chronic myeloid leukemia patients with high CIP2A levels is due to an antiapoptotic phenotype PMID: 26987906
16. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 PMID: 28174209
17. CIP2A is upregulated in MM, and CIP2A expression promotes cell proliferation and clonogenic formation ability by regulating the expression of AKT phosphorylation and c-Myc. PMID: 27484817
18. Gambogenic acid is a CIP2A inhibitor that interferes with the ubiquitination and destabilization of CIP2A. PMID: 27779687
19. Silencing CIP2A enhanced CuB-induced growth inhibition. PMID: 27350399
20. CIP2A copy number increase is associated with poor patient survival in human HNSCC. PMID: 26436875
21. low expression associates with chronic rhinosinusitis with nasal polyps with aspirin exacerbated respiratory disease PMID: 27348236
22. These results indicate that CIP2A modulates myeloma cell proliferation and apoptosis via PI3K/AKT/mTOR signaling and suggest that it can potentially serve as a drug target for the treatment of multiple myeloma. PMID: 27144172
23. CIP2A is involved in regulating multidrug resistance of cervical adenocarcinoma. PMID: 26404133
24. These results suggest that CIP2A is involved in tumor progression in bladder cancer PMID: 26243398
25. patients with a stronger expression of CIP2A in tgastric umor tissues had no significant relationship with these genes that are related to gastric cancer chemotherapy drug resistance PMID: 26823836
26. CIP2A levels were significantly associated with the American Joint Committee on Cancer (AJCC) stage, histological grade and lymph node metastasis in breast cancer patients. PMID: 26813457
27. CIP2A is a tumor-associated autoantigen in lung cancer, which promote lung cancer proliferation partially through MKK4/7-JNK signaling pathway. PMID: 26560124
28. CIP2A is a critical oncoprotein involved in cell invasion and epithelial mesenchymal transition in clear cell renal carcinoma. PMID: 26327467
29. Identify CIP2A as a common denominator for androgen receptor-signaling and prostate cancer stem cell functionality, and suggest as possible therapeutic target. PMID: 25965834
30. CIP2A was detected in tongue cancer and tongue hyperplasia, whereas local inflammation was stronger in cancer, CIP2A expression was increased in metastasized cancer compared to non-metastasized PMID: 26522733
31. CIP2A is an independent prognostic marker in patients with wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. PMID: 25896895
32. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer PMID: 25325377
33. Data show that afatinib reduced Elk-1 transcription factor binding to the CIP2A protein promoter and suppressed CIP2A transcription. PMID: 25537503
34. our findings strongly suggest that CIP2A promotes cell cycle progression, premature chromosome segregation, and aneuploidy, possibly through a novel interaction with Sgol1. PMID: 25736928
35. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. PMID: 26234767
36. The expression levels of mRNA for CIP2A and PP2A exhibited positive correlation in MDS/control bone marrow. PMID: 24163288
37. High cancerous inhibitor of PP2A (CIP2A) protein levels at diagnosis of chronic myeloid leukaemia are associated with disease progression in imatinib-treated patients PMID: 25765543
38. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance PMID: 25474139
39. Inhibition of CIP2A determines the effects of tamoxifen-induced apoptosis in estrogen receptor-negative breast cancer cells. PMID: 25228280
40. findings indicate tumor suppressor protein PP2A and its inhibitor CIP2A are widely distributed in meningiomas with a tendency for higher CIP2A expression in at least some higher-grade meningiomas; findings raise the possibility that CIP2A may participate in biology of meningiomas PMID: 25012485
41. The CIP2A-dependent pathway mediates the tumoricidal effects of erlotinib on NSCLC cells without EGFR mutations in vitro and in vivo. PMID: 24954871
42. CIP2A as a crucial oncoprotein has been involved in cell proliferation and apoptosis, which may serve as a therapeutic target in breast cancer treatment. PMID: 25086622
43. study addressed a novel role of CIP2A in mediating lung cancer progression through interacting with the AKT-mTOR signaling pathway. PMID: 25109354
44. CIP2A is overexpressed in chronic myelocytic leukemia patients.Cip2a plays an important role in the pathogenesis of chronic myelocytic leukemia. PMID: 25023053
45. Studies indicate that oncoprotein CIP2A (KIAA1524) controls oncogenic cellular signals by suppressing protein phosphatase 2A (PP2A). PMID: 25015035
46. High CIP2A expression is associated with cervical-cancer progression. PMID: 25458953
47. miR-218 is downregulated in melanoma. By targeting CIP2A and BMI1, miR-218 regulates the proliferation, migration, and invasion of the melanoma cell lines A375 and SK-MEL-2. PMID: 24839010
48. Downregulation of CIP2A suppresses cell proliferation and growth of nasopharyngeal carcinoma. PMID: 24884612
49. overexpression of CIP2A diminished NSCLC cell chemosensitivity to cisplatin by inducing activation of Akt pathway, suggesting critical roles of CIP2A in NSCLC cell chemoresistance to cisplatin PMID: 24874844
50. Estradiol enhances CIP2A expression by the activation of p70 S6 kinase. PMID: 24280132
顯示更多

收起更多
亞細胞定位：

Membrane; Single-pass membrane protein. Cytoplasm.
組織特異性：

Expressed at low levels in most of the tissues. Overexpressed in head-and-neck squamous cell carcinomas (HNSCC). Present in liver cancer cells (at protein level).
數據庫鏈接：

HGNC: 29302

OMIM: 610643

KEGG: hsa:57650

STRING: 9606.ENSP00000295746

UniGene: Hs.591308

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human